 Connection
Bradley Corr to Phenylurea Compounds
This is a "connection" page, showing publications Bradley Corr has written about Phenylurea Compounds.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.490 |
|
|
|
-
Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V. Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors. Int J Gynecol Cancer. 2025 Sep; 35(9):101812.
Score: 0.224
-
Gonz?lez-Mart?n A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. 2024 07; 186:182-190.
Score: 0.211
-
Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 Mar; 194:98-104.
Score: 0.056
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|